Human Biome Email Formats
Biotechnology Research • 
Warsaw, Masovian Voivodeship, Poland • 21-50 Employees
Human Biome Email Formats
Human Biome uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@human-biome.com), used 68.8% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@human-biome.com | 68.8% |
{first initial}.{last name} | j.doe@human-biome.com | 31.2% |
Key Contacts at Human Biome
Jarosław Biliński
Ceo
Grzegorz W. Basak
Co-Founder
Anna Wójtowicz-Krawiec
Vice Director
Company overview
| Headquarters | Działkowa, Warszawa, Mazowieckie 02-234, PL |
| Phone number | +48884299668 |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Drug Discovery, Microbiome, Immunology, Infection, Immunooncology, Graft Versus Host Disease, Live Biotherapeutic Products, Microbiome-Based Drugs |
| Founded | 2019 |
| Employees | 21-50 |
| Socials |
About Human Biome
The Human Biome was established as a Medical University of Warsaw spin-off due to the commercialization of our scientific research. Initially at the University, then at the Human Biome, in close cooperation with academia, since 2014, we conduct research on the gut microbiome as a new type of biotherapeutic agent. Having very rich baggage of experience in hematology, transplantation, immunology, and microbiology, we have combined many fields of medicine and technology to enter the world of the microbiome and discover what is undiscovered. HBI combines highly innovative microbiome knowledge and breakthrough technologies in one unique approach that is able to generate a pipeline of donor-independent New Generation Biotherapeutics (NGBs) as a Live Biotherapeutics Products (LBPs). Technologies and microbiome products developed by HBI: 1. “MicroDrug®” - AI/ML-based in-silico and ultra-deep tech in-vitro lab composing Drug Discovery Platform to predict microbiota-based drugs: - "Trapp MIcroBS" - in-silico computational platform predicting drug compositions - “Q Lab” - highly innovative in-vitro laboratory applying microfluidic, genomic, culturomic and robotic technologies to synthesize New Generation Biotherapeutics. 2. Microbiome Biobank - over 20 000 samples collected to date, from unique donors and patients (triads) treated by in-house produced highly rich and viable microbiota transplant preparations (Mbiotix) 3. Fecal Microbiota Transplantation (FMT) Facility with Clinical Platform (HBI leads 8 clinical experiments based on FMT to discover context-oriented drug compositions) 4. “Mbiotix” - highest-quality FMT preparation delivered to over 1400 patients. Currently, in the HBI pipeline are developed 4 New-Generation Biotherapeutics (NGB): - anti-CDI NGB (anti Clostridioides difficile NGB) - flagship anti-ARB/AI NGB (anti-antibiotic resistant bacteria and anti-infective NGB) - immunobooster NGB (GvHD and immunooncology) - longevity/wellbeing NGB.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Human Biome has 6 employees across 6 departments.
Departments
Number of employees
Funding Data
Human Biome has never raised funding before.
Human Biome Tech Stack
Discover the technologies and tools that power Human Biome's digital infrastructure, from frameworks to analytics platforms.
Web servers
Font scripts
JavaScript libraries
Tag managers
Form builders
Programming languages
Miscellaneous
Security
Blogs
JavaScript libraries
JavaScript libraries
Analytics
Spain
United States
Australia
Singapore
Israel
Canada
Mexico
Frequently asked questions
4.8
40,000 users
